Proteomic analysis to improve adequacy of hemo- and peritoneal dialysis: Removal of small and high molecular weight proteins with high- and low-flux filters or a peritoneal membrane

Proteomics - Clinical Applications

Volumn 2, Issue 7-8, 2008, Pages 1167-1182

  Dihazi, Hassan ^a   Müller, Claudia A ^b   Mattes, Harry ^a   Müller, Gerhard A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Department IV Internal Medicine   (Germany)

Author keywords

Continuous ambulatory peritoneal dialysis; Hemodialysis; High flux; Low flux; Peritoneum

Indexed keywords

PERFLUOROBUTYLTETRAHYDROFURAN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLEARANCE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE LEVEL; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEARANCE; PROTEIN MICROARRAY; PROTEIN TRANSPORT; REPRODUCIBILITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 50849123780     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780143     Document Type: Article

References (51)

1. Gansevoort, R. T., van der Heij, B., Stegeman, C. A., de Charro, F. T. et al., Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future? Kidney Int. Suppl. 2004, S7-10.
2. Vanholder, R., De Smet, R.,Pathophysiologic effects of uremic retention solutes. J. Am. Soc. Nephrol. 1999, 10, 1815-1823.
3. Vanholder, R., De Smet, R., Glorieux, G., Argiles, A. et al., Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003, 63, 1934-1943.
4. Vanholder, R., Glorieux, G., Lameire, N., New insights in uremic toxicity. Contrib. Nephrol. 2005, 149, 315-324.
5. Chelamcharla, M., Leypoldt, J. K., Cheung, A. K., Dialyzer membranes as determinants of the adequacy of dialysis. Semin. Nephrol. 2005, 25, 81-89.
6. Eknoyan, G.,Introduction: Adequacy of dialysis: Problems and challenges. Semin. Nephrol. 2005, 25, 67-69.
7. The National Cooperative Dialysis Study. Kidney Int. Suppl. 1983, S1-122.
8. Bloembergen, W. E., Stannard, D. C., Port, F. K., Wolfe, R. A. et al., Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int. 1996, 50, 557-565.
9. Parker, T. F. III, Husni, L., Huang, W., Low, N., Lowrie, E. G., Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am. J. Kidney Dis. 1994, 23, 670-680.
10. Bammens, B., Evenepoel, P., Verbeke, K., Vanrenterghem, Y., Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003, 64, 2238-2243.
11. Yavuz, A., Tetta, C., Ersoy, F. F., D'Intini, V. et al., Uremic toxins: A new focus on an old subject. Semin. Dial. 2005, 18, 203-211.
12. Locatelli, F., Dose of dialysis, convection and haemodialysis patients outcome - What the HEMO study doesn't tell us: The European viewpoint. Nephrol. Dial. Transplant. 2003, 18, 1061-1065.
13. Woods, H. F., Nandakumar, M., Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol. Dial. Transplant. 2000, 15 Suppl 1, 36-42.
14. Rayner, H. C., Pisoni, R. L., Bommer, J., Canaud, B. et al., Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2004, 19, 108-120.
15. Dihazi, H.,Clinical proteomics: An insight into the urinary proteome. Interview with Dr. Hassan Dihazi. Expert Rev. Proteomics 2006, 3, 481-482.
16. Dihazi, H., Muller, G. A., Urinary proteomics: A tool to discover biomarkers of kidney diseases. Expert Rev. Proteomics 2007, 4, 39-50.
17. Dihazi, H., Muller, G. A., Lindner, S., Meyer, M. et al., Characterization of diabetic nephropathy by urinary proteomic analysis: Identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem. 2007, 53, 1636-1645.
18. Gessner, C., Dihazi, H., Brettschneider, S., Hammerschmidt, S. et al., Presence of cytokeratins in exhaled breath condensate of mechanical ventilated patients. Respir. Med., 2007, 102, 299-306.
19. Jin, W. H., Dai, J., Li, S. J., Xia, Q. C. et al., Human plasma proteome analysis by multidimensional chromatography prefractionation and linear ion trap mass spectrometry identification. J. Proteome. Res. 2005, 4, 613-619.
20. Muller, G. A., Muller, C. A., Dihazi, H., Clinical proteomics - On the long way from bench to bedside? Nephrol. Dial. Transplant. 2007, 22, 1297-1300.
21. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., Liotta, L. A., Clinical proteomics: Translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 2002, 1, 683-695.
22. Pieper, R., Gatlin, C. L., Makusky, A. J., Russo, P. S. et al., The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003, 3, 1345-1364.
23. Kaiser, T., Hermann, A., Kielstein, J. T., Wittke, S. et al., Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. J. Chromatogr. A 2003, 1013, 157-171.
24. Lefler, D. M., Pafford, R. G., Black, N. A., Raymond, J. R., Arthur, J. M.,Identification of proteins in slow continuous ultrafiltrate by reversed-phase chromatography and proteomics. J. Proteome Res. 2004, 3, 1254-1260.
25. Molina, H., Bunkenborg, J., Reddy, G. H., Muthusamy, B. et al., A proteomic analysis of human hemodialysis fluid. Mol. Cell. Proteomics 2005, 4, 637-650.
26. Weissinger, E. M., Kaiser, T., Meert, N., De Smet, R. et al., Proteomics: A novel tool to unravel the patho-physiology of uraemia. Nephrol. Dial. Transplant. 2004, 19, 3068-3077.
27. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
28. Dihazi, H., Asif, A. R., Agarwal, N. K., Doncheva, Y., Muller, G. A., Proteomic analysis of cellular response to osmotic stress in thick ascending limb of Henle's loop (TALH) cells. Mol. Cell. Proteomics 2005, 4, 1445-1458.
29. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
30. Perkins, D. N., Pappin, D. J., Creasy, D. M., Cottrell, J. S., Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20, 3551-3567.
31. Towbin, H., Staehelin, T., Gordon, J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76, 4350-4354.
32. Churchill, D. N., Bird, D. R., Taylor, D. W., Beecroft, M. L. et al., Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. Am. J. Nephrol. 1992, 12, 412-418.
33. Kuchle, C., Fricke, H., Held, E., Schiffl, H., High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am. J. Nephrol. 1996, 16, 484-488.
34. Schiffl, H., Fischer, R., Lang, S. M., Mangel, E., Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrol. Dial. Transplant. 2000, 15, 840-845.
35. Hakim, R. M., Wingard, R. L., Husni, L., Parker, R. A., Parker, T. F. III, The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J. Am. Soc. Nephrol. 1996, 7, 472-478.
36. Burgi, W., Schmid, K., Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J. Biol. Chem. 1961, 236, 1066-1074.
37. Tada, T., Ohkubo, I., Niwa, M., Sasaki, M. et al., Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J. Histochem. Cytochem. 1991, 39, 1221-1226.
38. Henry, O. F., Blacher, J., Verdavaine, J., Duviquet, M., Safar, M. E., Alpha 1-acid glycoprotein is an independent predictor of in-hospital death in the elderly. Age Ageing 2003, 32, 37-42.
39. Haddad, J. G. Jr., Walgate, J., 25-Hydroxyvitamin D transport in human plasma. Isolation and partial characterization of calcifidiol-binding protein. J. Biol. Chem. 1976, 251, 4803-4809.
40. Kew, R. R., Fisher, J. A., Webster, R. O., Co-chemotactic effect of Gc-globulin (vitamin D binding protein) for C5a. Transient conversion into an active co-chemotaxin by neutrophils. J. Immunol. 1995, 155, 5369-6374.
41. Yamamoto, N., Homma, S., Haddad, J. G., Kowalski, M. A., Vitamin D3 binding protein required for in vitro activation of macrophages after alkylglycerol treatment of mouse peritoneal cells. Immunology 1991, 74, 420-424.
42. Lalloz, M. R., Byfield, P. G., Goel, K. M., Loudon, M. M. et al., Hyperthyroxinemia due to the coexistence of two raised affinity thyroxine-binding proteins (albumin and prealbumin) in one family. J. Clin. Endocrinol. Metab. 1987, 64, 346-352.
43. Moses, A. C., Lawlor, J., Haddow, J., Jackson, I. M., Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin. N. Engl. J. Med. 1982, 306, 966-969.
44. Moses, A. C., Rosen, H. N., Moller, D. E., Tsuzaki, S. et al., A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. J. Clin. Invest 1990, 86, 2025-2033.
45. Saraiva, M. J.,Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat. 2001, 17, 493-503.
46. Benson, M. D., Inherited amyloidosis. J. Med. Genet. 1991, 28, 73-78.
47. Jiang, X., Buxbaum, J. N., Kelly, J. W.,The V1221 cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. USA 2001, 98, 14943-14948.
48. Yi, S., Takahashi, K., Naito, M., Tashiro, F. et al., Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am. J. Pathol. 1991, 138, 403-412.
49. Ihi, T., Nakazato, M., Mukae, H., Matsukura, S., Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin. Infect. Dis. 1997, 25, 1134-1140.
50. Panyutich, A. V., Panyutich, E. A., Krapivin, V. A., Baturevich, E. A., Ganz, T., Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J. Lab Clin. Med. 1993, 122, 202-207.
51. Eknoyan, G., Beck, G. J., Cheung, A. K., Daugirdas, J. T. et al., Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002, 347, 2010-2019.